Semaglutide News and Research

Latest Semaglutide News and Research

Tirzepatide superior to semaglutide for blood sugar control and body weight loss

A new meta-analysis combining 22 studies, to be presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 October), shows that tirzepatide is superior to semaglutide for both control of blood sugar and in terms of amount of body weight lost by patients.

22 Sep 2023

Research reveals racial and ethnic disparities in the benefits of newer type 2 diabetes drugs

New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.

21 Sep 2023

KFF Health News' 'What the Health?': Countdown to shutdown

Health and other federal programs are at risk of shutting down, at least temporarily, as Congress races toward the Oct. 1 start of the fiscal year without having passed any of its 12 annual appropriations bills.

21 Sep 2023

KFF Health News' 'What the Health?': Underinsured is the new uninsured

The annual U.S. Census Bureau report this week revealed a drop in the uninsured rate last year as more working-age people obtained employer coverage.

14 Sep 2023

Unlocking the genetic code of blood sugar reveals new diabetes risks and lung complications

The study used a genome-wide association study (GWAS) to analyze random glucose levels in nearly half a million non-diabetic subjects, uncovering 150 distinct genetic signals, including 53 new ones, linked to glycemic traits and type 2 diabetes. The research also discovered a causal effect of random glucose and type 2 diabetes on lung function, identifying lung dysfunction as a new diabetes complication.

10 Sep 2023

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Groundbreaking research published today in Nature Genetics describes the largest-ever study into the genetics of random "round-the-clock" blood glucose levels.

8 Sep 2023

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

The study reveals that oral semaglutide, a medication primarily used for type 2 diabetes, effectively reduces body weight and blood glucose levels in diet-induced obese mice. The findings suggest that this drug could be a promising treatment for obesity and offer a suitable animal model for future research.

3 Sep 2023

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Researchers evaluated the efficacy of semaglutide in patients with the obesity phenotype of heart failure and preserved ejection fraction.

31 Aug 2023

Experts warn of unintended consequences of using GLP-1RAs to treat childhood obesity

A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children's health.

28 Aug 2023

Semaglutide could be a game-changer for patients with HFpEF and obesity

Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

25 Aug 2023

New ESC Guidelines for the management of cardiovascular disease in patients with diabetes released

Patients with type 2 diabetes are more than twice as likely to develop cardiovascular disease (CVD) than their healthy peers.

25 Aug 2023

FDA approves more drugs based on single trials and less public disclosure of results

The U.S. Food and Drug Administration is approving more novel pharmaceutical drugs based on single clinical trials and with less public disclosure about those trials than was the norm just a few years ago, a pair of recent studies from Oregon State University found.

24 Aug 2023

$9.57 million grant will support a clinical trial to study new treatment option for NAFLD

According to the National Institutes of Health, approximately 24% of adults in the United States have nonalcoholic fatty liver disease (NAFLD), an umbrella term for a range of liver conditions affecting people who drink little to no alcohol that can lead to cirrhosis, liver cancer and liver failure.

23 Aug 2023

Study finds altered brain connectivity in people with obesity

For the first time, researchers have discovered that the ventral tegmental area (VTA) of the brain - a key structure involved in motivation and reward appreciation has altered connectivity patterns with specific brain regions in patients with obesity.

22 Aug 2023

Study explores mechanism behind liraglutide-associated weight loss in obese individuals

A new study suggests that liraglutide is associated with the normalization of associative learning in obese individuals with insulin resistance.

22 Aug 2023

Obesity impairs brain's ability to learn associations

To control our behavior, the brain must be able to form associations. This involves, for example, associating a neutral external stimulus with a consequence following the stimulus (e.g., the hotplate glows red - you can burn your hand).

17 Aug 2023

Study: 93 million U.S. adults may benefit from semaglutide medication

Researchers from the University of California, Irvine have just published a study that projects 93 million U.S. adults that are overweight and obese may be suitable for the 2.4 mg dosage of semaglutide, a weight loss medication known under the brand name Wegovy.

16 Aug 2023

KFF Health News' 'What the Health?': On abortion rights, Ohio is the new Kansas

Ohio voters — in a rare August election — turned out in unexpectedly high numbers to defeat a ballot measure that would have made it harder to pass an abortion-rights constitutional amendment on the ballot in November.

10 Aug 2023

Revolutionizing type 2 diabetes treatment: personalized approach shows promise in matching patients with optimal glucose-lowering therapies

A personalized therapy selection algorithm for two diabetes type 2 (T2D) treatment drug classes.

10 Aug 2023

Seeking Medicare coverage for weight loss drugs, pharma giant courts Black influencers

Pharmaceutical giant Novo Nordisk has turned to influential Black Americans in pursuit of what would be a lucrative victory: having Medicare cover a new class of weight loss drugs, including the company's highly sought Wegovy, which can cost patients more than $1,000 a month.

8 Aug 2023

Semaglutide News and Research

Latest Semaglutide News and Research

Tirzepatide superior to semaglutide for blood sugar control and body weight loss

Research reveals racial and ethnic disparities in the benefits of newer type 2 diabetes drugs

KFF Health News' 'What the Health?': Countdown to shutdown

KFF Health News' 'What the Health?': Underinsured is the new uninsured

Unlocking the genetic code of blood sugar reveals new diabetes risks and lung complications

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Experts warn of unintended consequences of using GLP-1RAs to treat childhood obesity

Semaglutide could be a game-changer for patients with HFpEF and obesity

New ESC Guidelines for the management of cardiovascular disease in patients with diabetes released

FDA approves more drugs based on single trials and less public disclosure of results

$9.57 million grant will support a clinical trial to study new treatment option for NAFLD

Study finds altered brain connectivity in people with obesity

Study explores mechanism behind liraglutide-associated weight loss in obese individuals

Obesity impairs brain's ability to learn associations

Study: 93 million U.S. adults may benefit from semaglutide medication

KFF Health News' 'What the Health?': On abortion rights, Ohio is the new Kansas

Revolutionizing type 2 diabetes treatment: personalized approach shows promise in matching patients with optimal glucose-lowering therapies

Seeking Medicare coverage for weight loss drugs, pharma giant courts Black influencers

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Semaglutide News and Research

Latest Semaglutide News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in